Drugs / ExpressGraft-C9T1 Skin Tissue
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04134143 | Nov 2019 → Nov 2020 | diabetes mellitus, ulcer of lower limbs | Stratatech, a Mallinckrodt Company | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02657876 | Jan 2018 → May 2019 | diabetes mellitus, ulcer of lower limbs | Stratatech, a Mallinckrodt Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ExpressGraft-C9T1 Skin Tissue | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04134143 ↗ |
| Modality | Cell therapy | “biologically-active, circular skin tissue with a fully-stratified epithelial compartment comprised of human keratinocytes (NIKSC9T1) and a dermal compartment containing fibroblasts” NCT02657876 ↗ |